retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 is a triple-agonist drug targeting GLP-1, GIP, and receptors to suppress appetite and boost thermogenesis. trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing Retatrutide (GLP-3) — Peptide Triple

Risk of Retained Gastric Contents in Patients Using GLP-1RAs or Tirzepatide Presenting for Endoscopy or General Anesthesia Retrospective studies suggest that individuals on GLP-1-based therapy (exenatide, liraglutide, dulaglutide, semaglutide, or tirzepatide) appear to be at an increased risk of having retained gastric contents [Supplementary Table S3 (21)

Am J Pathol (2020) 190(2):40011

Low- and middle-income countries demonstrate rapid growth of type 2 diabetes: an analysis based on Global Burden of Disease 19902019 data

"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults" (PDF)

86 Finally, patients taking GLP-1RAs reduce caloric intake by 16%-39%, with some reporting 35%-40% reduction in high-fat food, 12.2% reduction in carbohydrate intake, and significant decreases in cravings for salty, spicy, dairy, and starchy foods